Another meta-analysis of clinical trials (n= 6745) revealed that canagliflozin reduced the levels of ALT, AST, and GGT in the serum of patients with T2DM after 26 or 52 weeks (Li et al., 2018[52]). The gene discussed is GPT; the disease is type 2 diabetes mellitus.